Study of Disease Severity and Quality of Life in Adults with Pemphigus and Bullous Pemphigoid

What this Trial Is About

Researchers are evaluating the severity and impact of autoimmune blistering diseases, specifically pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid. These diseases cause severe blistering and require new ways to measure disease severity accurately for use in clinical trials. The study aims to validate two key disease severity instruments, the Pemphigus Disease Area Index PDAI and the Bullous Pemphigoid Disease Area Index BPDAI, against other measures and to understand how these relate to patients quality of life. Participants will complete several questionnaires, including the PDAI, BPDAI, the Autoimmune Bullous Skin Disorder Intensity Score ABSIS, and various quality of life assessments such as the SF-36, Skindex-29, Dermatology Life Quality Index DLQI, Autoimmune Bullous Disease Quality of Life ABQOL, and Treatment of Autoimmune Bullous Disease Quality of Life TABQOL. Blood samples may also be donated to a blood bank for further immunologic and pathophysiologic studies. The study is observational and data is securely stored within a password-protected database. During the study, participants will be asked to rate their disease severity and complete quality of life questionnaires over a one-year period. The research team will use these assessments to compare disease severity scores and quality of life impacts. This study is conducted at the University of Pennsylvania and involves ongoing data collection to support future clinical trials for these conditions.

Autoimmune Blistering Diseases Study